Somerset, NJ May 11, 2012 — Thomas Feinberg, Ph.D., Director of Development & Clinical Services at Catalent Pharma Solutions, will deliver an update on the Parenteral and Ophthalmic Drug Products (PODP) working group entitled “What’s good for OINDP (Orally Inhaled and Nasal Drug Products) may not be good for PODP” at the E&L USA Conference 2012 on May 16, 2012.
Speaking on behalf of the Product Quality Research Institute (PQRI), Dr. Feinberg’s presentation will include an overview of how the PQRI is organized; the results of OINDP hypothesis testing; application to PODP and the PODP hypotheses; chemistry, toxicology and PODP Laboratory Work; and the process for building sound scientific justifications and consensus.
Catalent’s Development & Clinical Services support the rapid product development of pharmaceutical and biopharmaceutical products. In addition to an extensive range of analytical services the company offers regulatory consulting, clinical supply services and biologics cell line development. Catalent has made substantial recent investments to extend the capabilities and capacity of the business. Catalent today provides the broadest range of expert development services, which can drive more efficient development timelines, and help customers bring more compounds and better products to market faster.
Dr. Feinberg has over 15 years pharmaceutical analysis experience and over 25 years experience in mass spectrometry and spectroscopy.
Dr. Feinberg joined Magellan Labs at Research Triangle Park, North Carolina in 1995 and guided the growth of the Structural Chemistry department through both the Cardinal Health acquisition and the launch of Catalent Pharma Solutions.
In 2001, Dr. Feinberg was invited to join the PQRI OINDP Extractables and Leachables working group. He co-authored the recommendation “Safety Thresholds and Best Practices for Leachables and Extractables in Orally Inhaled and Nasal Drug Products (OINDPs)” and two chapters of Wiley’s definitive: “Leachables and Extractables Handbook: Safety Evaluation, Qualification, and Best Practices Applied to Inhalation Drug Products”.
Dr. Feinberg has been an active member of the Leachables and Extractables Parenteral Ophthalmic Drug Product (PODP) working group from its inception in 2008. He has written and presented extensively on extractables and leachables issues and advanced analytical chemistry techniques.
The E&L USA Conference starts on Wednesday, May 16th and continues the next day. There is a pre-conference workshop with an “Introduction to Extractables and Leachables Testing” on Tuesday, May 15th. Dr Feinberg’s presentation will take place at 11.10 Tremont Plaza Hotel and Grand Historic Venue in Baltimore. For more information on this event, please visit www.eandl-conference.com/extractables-and-leachables. To schedule an interview with Dr. Feinberg during or after the conference, please contact Patricia McGee at media@catalent.com.
To receive a copy of this presentation after the event, please visit us at www.catalent.com.
About Catalent
From drug and biologic development services to delivery technologies to supply solutions, Catalent Pharma Solutions has the deepest expertise, the broadest offerings and the most unique technologies in the industry. With over 75 years of experience, Catalent helps customers get more molecules to market faster, enhance product performance, and provide superior, reliable manufacturing and packaging solutions. Catalent employs approximately 9,400 people at 29 facilities worldwide and in fiscal year 2011 generated more than $1.6 billion in annual revenue. Catalent is headquartered in Somerset, NJ. For more information, visit www.catalent.com.
more products. better treatments. reliably supplied.™
Media Contacts:
Patricia McGee
+1 (732) 537 6407
patricia.mcgee@catalent.com
